Agile Therapeutics, Inc. (OTCQB:AGRX) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Matthew Riley - Head, IR & Corporate Communications Alfred Altomari - Chairman & CEO Dennis Reilly - SVP & CFO Conference Call Participants Oren Livnat - H.C. Wainwright & Co. Leland Gershell - Oppenheimer Timothy Lugo - William Blair & Company Nazibur Rahman - Maxim Group Operator Good afternoon, and welcome to the Agile Therapeutics' First Quarter 2021 Financial Results Conference Call. Pleas ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q4 2020 Earnings Conference Call March 1, 2021 4:30 PM ET Company Participants Matthew Riley - Investor Relations Alfred Altomari - Chairman, President & Chief Executive Officer Dennis Reilly - Senior Vice President & Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Leland Gershell - Oppenheimer Lachlan Hanbury-Brown - William Blair & Company Operator Ladies and gentlemen, thanks for standing by, and welcome to the Agile Therapeutics Fo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other jurisdictio ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q3 2020 Earnings Conference Call November 12, 2020 4:30 PM ET Company Participants Matthew Riley - Investor Relations Alfred Altomari - Chairman, President & Chief Executive Officer Dennis Reilly - Senior Vice President & Chief Financial Officer Conference Call Participants Randall Stanicky - RBC Capital Markets Oren Livnat - H.C. Wainwright Timothy Lugo - William Blair & Company Leland Gershell - Oppenheimer Paul Biedlingmaier - Edward Jones Operator Good afternoon and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or o ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q2 2020 Earnings Conference Call August 11, 2020 4:30 PM ET Company Participants Matthew Riley - Investor Relations Alfred Altomari - Chairman, President & Chief Executive Officer Dennis Reilly - Senior Vice President & Chief Financial Officer Conference Call Participants Daniel Busby - RBC Capital Markets Timothy Lugo - William Blair & Company Leland Gershell - Oppenheimer Oren Livnat - H.C. Wainwright Operator Greetings and welcome to the Agile Therapeutics Second Qua ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other ...